INTRODUCTION
Non-union fracture is one of the most difficult complications in orthopaedic. These cases often require readmission and surgery, which exaggerate the cost greatly, with an estimate of £13 844.68 for a single case of non-union [1, 2] . Besides the direct cost, the burden from the decreased productivity and quality of life also occurs, of which it costs $18 712 USD for one case [3] .
of non-union [4] . Abundant callus can be found in hypertrophic non-union, indicating ubiquitous blood, oxygen, and nutrient supply. It is considered to be a result of insufficient stability and treatment is directed toward stabilization of the fracture. In atrophic non-union, however, the pathophysiology remains unclear.
Dickson et al suggested poor vascularization as a cause of atrophic non-union [5] . Arterial occlusion in the ipsilateral extremity was associated with a higher rate of delayed union or non-union in open fractures of the tibia. However, Brownlow, Reed and Simpson found that in the animal model, the atrophic non-unions were well vascularized [6] .
Centeno et al have reported success in treatment of non-union fractures by percutaneous injection of autologous, culture-expanded, bone marrow-derived mesenchymal stem cells (MSCs). It seemed that lack of MSCs was the cause of the atrophic non-union fracture [7] .
In our previous study, we found that MSCs exist in the site of atrophic non-union fracture [8] . However, whether they are capable to differentiate into osteoblast was not evaluated. In the present study, we evaluate the osteogenic potency of MSCs from site of atrophic non-union fracture. Understanding the osteogenic potency of MSCs from site of atrophic non-union will help in better understanding of the unclear pathophysiology of atrophic non-union fracture.
METHODS
This was an in vitro experimental study. The study was conducted in Cipto Mangunkusumo Hospital and Regenerative and Cellular Therapy (ReGeniC) laboratory in Jakarta, Indonesia during the periods of July-December 2012. Sample was obtained from the non-union site of a 23-year-old patient with a 6-years-history of atrophic non-union fracture of right femur. During open reduction and internal fixation for atrophic non-union fracture, and before recanalization of the fracture, a 10 ml syringe prefilled with 2 ml heparin 1000 IU/ml was introduced until it reached the medullary canal. The plunger was then pulled to aspirate the marrow. The procedure was repeated until 10 ml of marrow was obtained. The surgery was then continued following the routine procedure.
Equivalent amount of phosphate buffer saline (PBS) was added to marrow aspirate. The solution was centrifuged at 3000 rpm, 20°C for 30 minutes. Pellet was re-suspended into a 75 cm 2 TC flasks with growth medium that contained low glucose Dulbecco's modified eagles medium (Gibco, Grand Island, New York) containing 1000 mg/L D-glucose, L-glutamine, 100 mg/L sodium pyruvate, and 10% fetal bovine serum. The suspension was incubated at 37°C, 20% oxygen and 5% CO 2 flow. After 7 days, the culture was washed several times with PBS and the medium was replaced with fresh medium every 3 day until confluence. Once the MSCs culture reach confluence, osteogenic differentiation was performed in monolayered MSC grown in both home-made and commercially available osteogenic media (MesenCult®) and incubated 37°C, 20% oxygen and 5% CO 2 flow. Home-made medium contained DMEM, 10% FBS, 1% antibiotics, 0.1μM dexamethasone, 50μM ascorbate-2-phosphate, 10mM β-glycerophosphate.
Confirmation
After 7 day, cells culture was washed several times with PBS and the medium was replaced with fresh medium every 3 day until confluence. Confluence in commercially available medium was reached in 5 weeks while all cells in the home-made medium failed to survive.
To evaluate osteogenic differentiation, we performed Alizarin red staining and colorimetric assay for alkaline phosphatase (ALP). Undifferentiated mesenchymal stem cells were used as negative control. Colorimetric assay was performed using Alkaline Phosphatase Colorimetric Assay Kit (Abcam, Cambridge, UK) containing p-nitrophenyl phosphate (pNPP) as a phosphatase substrate. Amount of 25 micro liter of cell lysate was prepared using three cycles of freeze-thaw in de-ionized distilled water. The cells lysate was added to a well plate with assay buffer and pNPP. The samples were shielded from direct light at room temperature for 1 h. Afterward, L Stop Solution (3N NaOH) was added to the wells and the plate was read at 405 nm in a micro-plate reader.
RESULTS
After 3 weeks, the MSCs were successfully isolated and expanded as observed by BMSCs attachment with fibroblast-like morphology appearance in a light microscope with 100x magnification. They were adherent to the TC flask and was not washed in the medium replacement. The confluence of cells was 80%-90% with total number of the cells 3.6 x106 and 2.2x106. (Figure 1 ) The MSCs characteristic was confirmed with ≥95% expression of CD105 and CD73 as well as its low expression (≤2%) of CD14, CD34, CD45, CD19, and HLA-DR. lagen I, TGF-B and fibronectin. Matrix maturation phase is characterized by maximal expression of alkaline phosphatase. During matrix mineralization, proteins such as osteocalsin, bone sialoprotein, and osteopontin are expressed, Calcium deposition during this phase can also be evaluated using adequate staining methods such as Alizarin red.
Marom et al reported ALP was expressed during early stage of differentiation and was involved with matrix mineralization. [16] Alizarin red is a staining method to determine the presence of calcific deposition by cells of an osteogenic lineage during mineralization phase. It is an early stage marker of matrix mineralization [17] [18] . The presence of ALP activity and positive Alizarin red staining in our study showed that MSCs stem cells obtained from site of atrophic non-union is capable to be differentiated into osteogenic cells.
Although our study is limited only to one sample, it is a preliminary result for further evaluation of osteogenic potency of mesenchymal stem cells obtained from site of atrophic non-union. Confirmation of this finding will lead to better understanding of pathophysiology of atrophic non-union and improvement in management strategy.
In conclusion, our preliminary study found the possible osteogenic potency of mesenchymal stem cells obtained from non-union site. 
DISCUSSION
In our previous study, we revealed the existence of mesenchymal stem cells in atrophic non-union fracture site [8] . However, in our, we did not evaluate the osteogenic potency of those cells in the study. In this study, we evaluated the osteogenic potency of mesenchymal stem cells in the site of atrophic non-union fractures.
Characterization of cells obtained from the site of atrophic non-union fracture confirmed the presence of mesenchymal stem cells. The cells that we obtained were able to adhere to plastic in standard culture condition, positive expression on CD 105, CD 73, CD 90 for at least 95%, negative expression of CD 45, CD 34, CD 14 or CD 11b, CD 79a, and HLA-DR [9] .
Despite similar constituents, we found failure of our home-made medium to induce differentiation of MSCs into osteogenic cells. [10] All cells died before 5 weeks and none was left for further evaluation. The failure might due to the imprecise composition of the medium that influence the milieu. Further researches must be done to evaluate the effect of this homemade osteogenic medium upon its capability in inducing osteogenic differentiation of MSCs. Addition of various chemical substances had been reported to increase the success of osteogenic differentiation [11] [12] [13] .
Osteogenic differentiation of MSCs can be characterized by various technique, depending on the development stage of the cells; cells proliferation, matrix maturation, and matrix mineralization [14] [15] .
During cells proliferation, several extracellular matrix proteins can be detected, such as procol-
